Aim The cardiovascular benefits provided by glucagon‐like peptide‐1 receptor agonists
(GLP‐1RAs) extend beyond weight reduction and glycaemic control. One possible …

Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD)
worldwide. Its pathogenesis encompasses functional alterations involving elevated …

Transient permeability enhancers (PEs), such as caprylate, caprate, and salcaprozate
sodium (SNAC), improve the bioavailability of poorly permeable macromolecular drugs …

Metformin is the currently accepted first-line treatment for antipsychotic-associated weight
gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 …

Purpose Chronic kidney disease (CKD) is one of the most common complications of type 2
diabetes (T2D), and CKD-related disability and mortality are increasing despite the recent …

Introduction In this phase 4, multicentre, prospective, non-interventional PIONEER REAL
Netherlands study, we assessed clinical outcomes associated with once-daily oral …

Objectives To evaluate the efficacy and safety of the glucagon-like peptide-1 (GLP-1)
receptor agonist (RA) oral semaglutide in the treatment of type 2 diabetes mellitus (T2DM) …

Background In clinical trials enrolling patients with type 2 diabetes (T2D) at high
cardiovascular risk, many glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improved …

Objective To evaluate the blood pressure (BP) lowering ability of semaglutide, a glucagon-
like peptide-1 receptor agonist (GLP-1 RA), in individuals with type-2 diabetes (T2D) …

Background As new antidiabetic drugs, tirzepatide (Tir) and semaglutide (Sem) are
progressively applied in clinical practice. However, their efficacy and safety profiles have not …